Global Omalizumab Injection Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Omalizumab Injection Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Pre-Filled Subcutaneous Injection Solution
- 1.3.3 Lyophilized Subcutaneous Injection Solution
- 1.4 Market Analysis by Specifications
- 1.4.1 Overview: Global Omalizumab Injection Consumption Value by Specifications: 2021 Versus 2025 Versus 2032
- 1.4.2 75mg
- 1.4.3 100mg
- 1.4.4 150mg
- 1.5 Market Analysis by Purity
- 1.5.1 Overview: Global Omalizumab Injection Consumption Value by Purity: 2021 Versus 2025 Versus 2032
- 1.5.2 More than 99.0%
- 1.5.3 98.5%-99%
- 1.5.4 98.0%-98.5%
- 1.6 Market Analysis by Application
- 1.6.1 Overview: Global Omalizumab Injection Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.6.2 Allergic Asthma
- 1.6.3 Chronic Spontaneous Urticaria (CSU)
- 1.7 Global Omalizumab Injection Market Size & Forecast
- 1.7.1 Global Omalizumab Injection Consumption Value (2021 & 2025 & 2032)
- 1.7.2 Global Omalizumab Injection Sales Quantity (2021-2032)
- 1.7.3 Global Omalizumab Injection Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 Novartis
- 2.1.1 Novartis Details
- 2.1.2 Novartis Major Business
- 2.1.3 Novartis Omalizumab Injection Product and Services
- 2.1.4 Novartis Omalizumab Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Novartis Recent Developments/Updates
- 2.2 Celltrion
- 2.2.1 Celltrion Details
- 2.2.2 Celltrion Major Business
- 2.2.3 Celltrion Omalizumab Injection Product and Services
- 2.2.4 Celltrion Omalizumab Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Celltrion Recent Developments/Updates
- 2.3 Reliance
- 2.3.1 Reliance Details
- 2.3.2 Reliance Major Business
- 2.3.3 Reliance Omalizumab Injection Product and Services
- 2.3.4 Reliance Omalizumab Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Reliance Recent Developments/Updates
- 2.4 Genentech
- 2.4.1 Genentech Details
- 2.4.2 Genentech Major Business
- 2.4.3 Genentech Omalizumab Injection Product and Services
- 2.4.4 Genentech Omalizumab Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 Genentech Recent Developments/Updates
3 Competitive Environment: Omalizumab Injection by Manufacturer
- 3.1 Global Omalizumab Injection Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Omalizumab Injection Revenue by Manufacturer (2021-2026)
- 3.3 Global Omalizumab Injection Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Omalizumab Injection by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Omalizumab Injection Manufacturer Market Share in 2025
- 3.4.3 Top 6 Omalizumab Injection Manufacturer Market Share in 2025
- 3.5 Omalizumab Injection Market: Overall Company Footprint Analysis
- 3.5.1 Omalizumab Injection Market: Region Footprint
- 3.5.2 Omalizumab Injection Market: Company Product Type Footprint
- 3.5.3 Omalizumab Injection Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Omalizumab Injection Market Size by Region
- 4.1.1 Global Omalizumab Injection Sales Quantity by Region (2021-2032)
- 4.1.2 Global Omalizumab Injection Consumption Value by Region (2021-2032)
- 4.1.3 Global Omalizumab Injection Average Price by Region (2021-2032)
- 4.2 North America Omalizumab Injection Consumption Value (2021-2032)
- 4.3 Europe Omalizumab Injection Consumption Value (2021-2032)
- 4.4 Asia-Pacific Omalizumab Injection Consumption Value (2021-2032)
- 4.5 South America Omalizumab Injection Consumption Value (2021-2032)
- 4.6 Middle East & Africa Omalizumab Injection Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Omalizumab Injection Sales Quantity by Type (2021-2032)
- 5.2 Global Omalizumab Injection Consumption Value by Type (2021-2032)
- 5.3 Global Omalizumab Injection Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Omalizumab Injection Sales Quantity by Application (2021-2032)
- 6.2 Global Omalizumab Injection Consumption Value by Application (2021-2032)
- 6.3 Global Omalizumab Injection Average Price by Application (2021-2032)
7 North America
- 7.1 North America Omalizumab Injection Sales Quantity by Type (2021-2032)
- 7.2 North America Omalizumab Injection Sales Quantity by Application (2021-2032)
- 7.3 North America Omalizumab Injection Market Size by Country
- 7.3.1 North America Omalizumab Injection Sales Quantity by Country (2021-2032)
- 7.3.2 North America Omalizumab Injection Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Omalizumab Injection Sales Quantity by Type (2021-2032)
- 8.2 Europe Omalizumab Injection Sales Quantity by Application (2021-2032)
- 8.3 Europe Omalizumab Injection Market Size by Country
- 8.3.1 Europe Omalizumab Injection Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Omalizumab Injection Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Omalizumab Injection Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Omalizumab Injection Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Omalizumab Injection Market Size by Region
- 9.3.1 Asia-Pacific Omalizumab Injection Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Omalizumab Injection Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Omalizumab Injection Sales Quantity by Type (2021-2032)
- 10.2 South America Omalizumab Injection Sales Quantity by Application (2021-2032)
- 10.3 South America Omalizumab Injection Market Size by Country
- 10.3.1 South America Omalizumab Injection Sales Quantity by Country (2021-2032)
- 10.3.2 South America Omalizumab Injection Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Omalizumab Injection Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Omalizumab Injection Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Omalizumab Injection Market Size by Country
- 11.3.1 Middle East & Africa Omalizumab Injection Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Omalizumab Injection Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Omalizumab Injection Market Drivers
- 12.2 Omalizumab Injection Market Restraints
- 12.3 Omalizumab Injection Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Omalizumab Injection and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Omalizumab Injection
- 13.3 Omalizumab Injection Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Omalizumab Injection Typical Distributors
- 14.3 Omalizumab Injection Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
According to our (Global Info Research) latest study, the global Omalizumab Injection market size was valued at US$ 5518 million in 2025 and is forecast to a readjusted size of US$ 8274 million by 2032 with a CAGR of 6.1% during review period.
Omalizumab injection is a targeted biological agent. It is a humanized monoclonal antibody that can precisely bind to and block immunoglobulin E (IgE), thereby preventing the release of inflammatory mediators such as histamine. It is often used to treat allergic asthma and chronic spontaneous urticaria (CSU) that do not respond well to traditional drugs (such as antihistamines), allowing patients to get rid of the troubles caused by allergic reactions and improve their quality of life.
Global production of omalizumab injection is projected to reach 7.15 million vials by 2025, with an average price of $750 per vial. Gross profit margins typically range from 65% to 80%.
The upstream supply chain of omalizumab injection mainly includes culture media and additives required for recombinant cell line construction and culture, protein purification resins and filtration consumables, disposable bioreactors and aseptic filling consumables, and packaging materials such as pre-filled glass needles or vials. The upstream supply chain has extremely high requirements for quality consistency and compliance systems. Downstream applications are the core of demand, mainly concentrated in the treatment of immune-related diseases such as severe allergic asthma and chronic spontaneous urticaria. In clinical settings, omalizumab, as an IgE-targeting biologic, is typically used for patients with insufficient response to conventional treatments, with a clear evidence-based medical foundation. It is mainly used in the respiratory, allergy, and dermatology departments of tertiary hospitals. With guideline recommendations and the accumulation of real-world data, its position in standardized long-term management is solid. In terms of payment, inclusion in medical insurance and local supplementary insurance plays a decisive role in increasing sales volume, and patient compliance and ease of administration directly affect the usage structure. Downstream customers are primarily hospitals and the medical insurance system, resulting in highly concentrated procurement, significant price negotiation, and barriers to entry.
The industry's development trend is characterized by the gradual market launch of biosimilars, driving down prices and improving accessibility. Simultaneously, optimized subcutaneous administration and an expanded patient population are contributing to structural growth. The main driving factors are the rising prevalence of allergic diseases, the promotion of standardized treatment, and expanded medical insurance coverage. Obstacles include intensified competition among biosimilars, price pressure from centralized volume-based procurement, and the substitution risk from other new mechanism biologics.
This report is a detailed and comprehensive analysis for global Omalizumab Injection market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Omalizumab Injection market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Omalizumab Injection market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Omalizumab Injection market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Omalizumab Injection market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Omalizumab Injection
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Omalizumab Injection market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Celltrion, Reliance, Genentech, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Omalizumab Injection market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Pre-Filled Subcutaneous Injection Solution
Lyophilized Subcutaneous Injection Solution
Market segment by Specifications
75mg
100mg
150mg
Market segment by Purity
More than 99.0%
98.5%-99%
98.0%-98.5%
Market segment by Application
Allergic Asthma
Chronic Spontaneous Urticaria (CSU)
Major players covered
Novartis
Celltrion
Reliance
Genentech
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Omalizumab Injection product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Omalizumab Injection, with price, sales quantity, revenue, and global market share of Omalizumab Injection from 2021 to 2026.
Chapter 3, the Omalizumab Injection competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Omalizumab Injection breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Omalizumab Injection market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Omalizumab Injection.
Chapter 14 and 15, to describe Omalizumab Injection sales channel, distributors, customers, research findings and conclusion.